1.15
price down icon5.74%   -0.07
after-market Handel nachbörslich: 1.15
loading
Schlusskurs vom Vortag:
$1.22
Offen:
$1.18
24-Stunden-Volumen:
758.96K
Relative Volume:
1.14
Marktkapitalisierung:
$72.55M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-0.7278
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
-22.30%
1M Leistung:
-49.56%
6M Leistung:
-67.61%
1J Leistung:
-91.59%
1-Tages-Spanne:
Value
$1.10
$1.19
1-Wochen-Bereich:
Value
$1.10
$1.51
52-Wochen-Spanne:
Value
$1.10
$19.54

Macrogenics Inc Stock (MGNX) Company Profile

Name
Firmenname
Macrogenics Inc
Name
Telefon
301-251-5172
Name
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Name
Mitarbeiter
0
Name
Twitter
@macrogenics
Name
Nächster Verdiensttermin
2025-03-07
Name
Neueste SEC-Einreichungen
Name
MGNX's Discussions on Twitter

Vergleichen Sie MGNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MGNX
Macrogenics Inc
1.15 72.55M 139.77M -97.62M -61.71M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-07 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2024-08-01 Herabstufung BTIG Research Buy → Neutral
2024-07-31 Herabstufung B. Riley Securities Buy → Neutral
2024-07-31 Herabstufung Guggenheim Buy → Neutral
2024-05-10 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-05-10 Herabstufung Stifel Buy → Hold
2024-05-10 Herabstufung TD Cowen Buy → Hold
2024-04-26 Eingeleitet B. Riley Securities Buy
2024-04-09 Hochstufung TD Cowen Hold → Buy
2024-03-04 Bestätigt BTIG Research Buy
2024-02-14 Herabstufung H.C. Wainwright Buy → Neutral
2023-12-20 Hochstufung Citigroup Neutral → Buy
2023-11-07 Hochstufung Guggenheim Neutral → Buy
2023-03-17 Herabstufung Guggenheim Buy → Neutral
2022-11-22 Herabstufung Cowen Outperform → Market Perform
2022-11-14 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-07-18 Herabstufung SMBC Nikko Outperform → Neutral
2022-07-11 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-05-04 Herabstufung Guggenheim Buy → Neutral
2022-02-28 Hochstufung Citigroup Neutral → Buy
2022-02-11 Eingeleitet BMO Capital Markets Outperform
2022-02-04 Eingeleitet SMBC Nikko Outperform
2021-11-17 Fortgesetzt Guggenheim Buy
2021-10-19 Eingeleitet JMP Securities Mkt Outperform
2021-10-15 Fortgesetzt BTIG Research Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-12 Hochstufung Barclays Underweight → Overweight
2020-12-22 Fortgesetzt H.C. Wainwright Buy
2020-08-03 Herabstufung Citigroup Buy → Neutral
2020-06-01 Hochstufung Guggenheim Neutral → Buy
2020-05-26 Bestätigt H.C. Wainwright Buy
2020-03-04 Eingeleitet Barclays Underweight
2019-12-19 Eingeleitet Cantor Fitzgerald Overweight
2019-12-18 Eingeleitet Cantor Fitzgerald Overweight
2019-11-21 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-11-20 Fortgesetzt Guggenheim Neutral
2019-05-03 Hochstufung Wedbush Neutral → Outperform
2019-04-12 Eingeleitet Guggenheim Neutral
2019-02-07 Hochstufung Citigroup Sell → Buy
2019-02-07 Herabstufung Wedbush Outperform → Neutral
2019-02-06 Hochstufung Raymond James Underperform → Mkt Perform
2019-02-04 Herabstufung Citigroup Neutral → Sell
2018-12-10 Herabstufung Raymond James Outperform → Underperform
2018-09-10 Fortgesetzt BTIG Research Buy
2018-05-31 Eingeleitet Evercore ISI Outperform
2018-03-05 Eingeleitet H.C. Wainwright Buy
2017-03-31 Eingeleitet Raymond James Outperform
Alle ansehen

Macrogenics Inc Aktie (MGNX) Neueste Nachrichten

pulisher
09:35 AM

MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

09:35 AM
pulisher
Mar 30, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

HC Wainwright Increases Earnings Estimates for MacroGenics - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire

Mar 27, 2025
pulisher
Mar 26, 2025

MacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC Wainwright - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

MGNX stock touches 52-week low at $1.88 amid market challenges - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

MGNX stock touches 52-week low at $1.88 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

MacroGenics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 24, 2025

Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical - openPR.com

Mar 24, 2025
pulisher
Mar 24, 2025

Macrogenics Inc (NASDAQ: MGNX) Analysts Prediction On How Much It Could Rise - Stocks Register

Mar 24, 2025
pulisher
Mar 24, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Consensus Price Target from Analysts - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 23, 2025
pulisher
Mar 23, 2025

MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook - Investing.com Canada

Mar 23, 2025
pulisher
Mar 23, 2025

StockNews.com Downgrades MacroGenics (NASDAQ:MGNX) to Hold - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook By Investing.com - Investing.com South Africa

Mar 22, 2025
pulisher
Mar 21, 2025

MacroGenics Inc’s 2024 Earnings Call Highlights - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

MacroGenics axes ADC drug following Phase II failure in prostate cancer - Yahoo

Mar 21, 2025
pulisher
Mar 21, 2025

Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahea - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

Stifel maintains Hold on MacroGenics stock, price target at $6 By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Citizens JMP maintains MacroGenics stock with Market Outperform By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Citizens JMP maintains MacroGenics stock with Market Outperform - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

MacroGenics Reports 2024 Financial Results and Progress - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses - Yahoo Finance

Mar 21, 2025
pulisher
Mar 20, 2025

MacroGenics (MGNX) Q4 2024 Earnings Call Transcript - Yahoo

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

MACROGENICS Earnings Results: $MGNX Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Inc. (MGNX) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Inc Provides Update On Corporate Progress And 2024 Financial Results - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Macrogenics Inc (MGNX) Reports Q4 Revenue of $150 Million, Surpa - GuruFocus

Mar 20, 2025
pulisher
Mar 20, 2025

MACROGENICS INC SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Triples Revenue to $150M as Cancer Drug Pipeline Advances - StockTitan

Mar 20, 2025
pulisher
Mar 18, 2025

MGNX stock touches 52-week low at $2.15 amid sharp annual decline - Investing.com Australia

Mar 18, 2025
pulisher
Mar 17, 2025

Macrogenics Stock Drops 77% After Study Deaths - The Wall Street Journal

Mar 17, 2025
pulisher
Mar 17, 2025

Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 13, 2025

MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 12, 2025
pulisher
Mar 12, 2025

MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com

Mar 12, 2025
pulisher
Mar 11, 2025

MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 09, 2025

MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 06, 2025

Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 06, 2025

Finanzdaten der Macrogenics Inc-Aktie (MGNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):